In this fireside chat-style conversation, Dr. Eric Stahlberg (Frederick National Laboratory) and Dr. David Lindsay (Leidos Biomedical Research) discussed how digital twins have the potential to transform health care and pave the way for new therapies to treat cancers and address other health challenges.
A digital twin is a virtual representation – or digital counterpart – of a physical object or process. Digital twins are used in a wide variety of fields ranging from aerospace engineering, to financial services. In health care, a digital twin can serve as a crucial substitute of the human body, allowing scientists and clinicians to leverage data to examine possible treatment outcomes.
During this event, Dr. Lindsay interviewed Dr. Stahlberg about the potential for digital twins to transform health care – particularly in the realm of cancer care. In addition, Dr. Lindsay shared his own perspective on how advances in biomedical research are pointing to new avenues for vaccine development and infectious disease treatment.
Dr. David A. Lindsay is Senior Vice President at Leidos Biomedical Research (LBR); he is currently the Directorate Head of the Vaccine Clinical Materials Program (VCMP), having served the Frederick National Lab in this role the past 7 years. He represents the VCMP on the Executive Leadership Team at LBR. Since 2018, Dr. Lindsay has also served on the University of Maryland’s Fischell Department of Bioengineering advisory board. Dr. Lindsay is a scientific/technical leader, with oversight and accountable for all manufacturing, quality control, facility operations, subcontracting, and administrative activities of a GMP vaccine pilot plant under contract to the National Cancer Institute. Dr. Lindsay is a chemical engineer by education, having obtained a B.S. from Lafayette College and a doctorate from Johns Hopkins University. He has 27 years of bioprocessing industry experience, having trained at Schering-Plough Research Institute in New Jersey and subsequently at MedImmune in Maryland.
Dr. Eric Stahlberg is director of Biomedical Informatics and Data Science at the Frederick National Laboratory for Cancer Research (FNL) and co-lead for ATOM. He has served in leadership roles for many key partnerships and is a co-lead of the strategic interagency collaboration between the National Cancer Institute and the U.S. Department of Energy (the NCI-DOE Collaboration). Programs include the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C), ATOM and CANDLE. Dr. Stahlberg spearheaded the Laboratory’s contributions to the NCI-DOE Collaboration programs and directs FNL activities to expand engagement with the broader cancer research community, including interdisciplinary projects to advance development of cancer patient digital twin approaches and creation of innovative approaches for radiation oncology. In 2017, he was recognized as one of FCW's Federal 100. He earned a Ph.D. in computational chemistry and B.A. degrees in computer science, chemistry and mathematics.